- Agilent Technologies Inc. to acquire BIOVECTRA for $925 million.
- The acquisition expands Agilent’s CDMO services and capabilities in biologics and gene editing.
Agilent Technologies Inc. has announced a definitive agreement to acquire BIOVECTRA, a specialized contract development and manufacturing organization (CDMO), for $925 million. The acquisition aims to enhance Agilent’s capabilities in biologics, highly potent active pharmaceutical ingredients, and other targeted therapeutics.
BIOVECTRA, based in Canada, will bring its expertise in sterile fill-finish services, pDNA and mRNA capabilities, and lipid nanoparticle (LNP) formulation to Agilent. This acquisition will also add rapidly growing modalities such as antibody drug conjugates (ADCs), highly potent active pharmaceutical ingredients (HPAPIs), and GLP-1 to Agilent’s portfolio. Additionally, BIOVECTRA’s capabilities in biologics, combined with Agilent’s expertise in gRNA, will provide customers with a single source for gene-editing technology.
Both companies are fully integrated CDMOs with facilities adhering to current Good Manufacturing Practices (cGMP). “We look forward to welcoming BIOVECTRA to Agilent,” said Agilent President and CEO Padraig McDonnell. “The company has an outstanding record of innovation, and its employees share our commitment to providing integrated biopharma solutions that continuously deliver more value to customers.”
BIOVECTRA’s CEO, Oliver Technow, expressed excitement about the acquisition, stating, “BIOVECTRA is excited to join Agilent, a company whose dedication to people and customers is very much aligned with ours. This synergistic pairing of our capabilities with Agilent’s will further enhance the value we can offer to our customers.”
Overview of outsourcing trends 
